GPER1 and obesity disorder: reported that GPR30 agonism with GPR30-selective small-molecule agonist G-1 reverses OVX-induced obesity by decreasing body weight and fat mass, increasing energy expenditure, promoting BAT remodeling, improving glucose homeostasis, and lowering pro-inflammatory responses.